Want to see SG:42C full AI Analyst Report?
iX Biopharma Ltd. (42C) Stock Statistics & Valuation Metrics
Total Valuation
iX Biopharma Ltd. has a market cap or net worth of SGD 558.96M. The enterprise value is SGD 375.67M.
- Market Cap
- SGD 558.96M
- Enterprise Value
- SGD 375.67M
Share Statistics
iX Biopharma Ltd. has 1,095,998,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 1,095,998,300
- Owned by Insiders
- 24.18%
- Owned by Institutions
- 0.09%
Financial Efficiency
iX Biopharma Ltd.’s return on equity (ROE) is -0.52 and return on invested capital (ROIC) is -44.68%.
- Return on Equity (ROE)
- -0.52
- Return on Assets (ROA)
- -0.31
- Return on Invested Capital (ROIC)
- -44.68%
- Return on Capital Employed (ROCE)
- -0.60
- Revenue Per Employee
- 185.22K
- Profits Per Employee
- -216.03K
- Employee Count
- 37
- Asset Turnover
- 0.26
- Inventory Turnover
- 3.70
Valuation Ratios
The current PE Ratio of iX Biopharma Ltd. is -61.45. iX Biopharma Ltd.’s PEG ratio is 1.86.
- PE Ratio
- -61.45
- PS Ratio
- 81.56
- PB Ratio
- 0.03
- Price to FCF
- -98.43
- Price to Operating Cash Flow
- -0.10
- PEG Ratio
- 1.86
Income Statement
In the last 12 months, iX Biopharma Ltd. had revenue of 6.85M and earned -7.99M in profits. Earnings per share was -0.01.
- Revenue
- 6.85M
- Gross Profit
- 2.43M
- Operating Income
- -9.56M
- Pretax Income
- -7.98M
- Net Income
- -7.99M
- EBITDA
- -8.83M
- Earnings Per Share (EPS)
- -0.01
Cash Flow
In the last 12 months, operating cash flow was -5.57M and capital expenditures -114,000, giving a free cash flow of -5.68M billion.
- Operating Cash Flow
- -5.57M
- Free Cash Flow
- -5.68M
- Free Cash Flow per Share
- -5.39
Dividends & Yields
iX Biopharma Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.02%
- Earnings Yield
- -1487.36%
Stock Price Statistics
- Beta
- -0.07
- 52-Week Price Change
- 332.20%
- 50-Day Moving Average
- 0.51
- 200-Day Moving Average
- 0.38
- Relative Strength Index (RSI)
- 50.98
- Average Volume (3m)
- 16.77M
Important Dates
iX Biopharma Ltd. upcoming earnings date is Feb 05, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 21, 2026
- Next Earnings Date
- Feb 05, 2027
- Ex-Dividend Date
- ―
Financial Position
iX Biopharma Ltd. as a current ratio of 1.86, with Debt / Equity ratio of 37.68%
- Current Ratio
- 1.86
- Quick Ratio
- 1.74
- Debt to Market Cap
- 0.02
- Net Debt to EBITDA
- 1.01
- Interest Coverage Ratio
- -13.86
Taxes
In the past 12 months, iX Biopharma Ltd. has paid 9,000 in taxes.
- Income Tax
- 9,000
- Effective Tax Rate
- -0.00
Enterprise Valuation
iX Biopharma Ltd. EV to EBITDA ratio is -59.80, with an EV/FCF ratio of -96.85.
- EV to Sales
- 80.26
- EV to EBITDA
- -59.80
- EV to Free Cash Flow
- -96.85
- EV to Operating Cash Flow
- -98.84
Balance Sheet
iX Biopharma Ltd. has SGD 14.73M in cash and marketable securities with SGD 5.80M in debt, giving a net cash position of SGD 8.93M billion.
- Cash & Marketable Securities
- SGD 14.73M
- Total Debt
- SGD 5.80M
- Net Cash
- SGD 8.93M
- Net Cash Per Share
- SGD 0.01
- Tangible Book Value Per Share
- SGD 14.61
Margins
Gross margin is 35.52%, with operating margin of -139.52%, and net profit margin of -116.64%.
- Gross Margin
- 35.52%
- Operating Margin
- -139.52%
- Pretax Margin
- -116.50%
- Net Profit Margin
- -116.64%
- EBITDA Margin
- -134.22%
- EBIT Margin
- -139.52%
Analyst Forecast
The average price target for iX Biopharma Ltd. is SGD 1.03, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- SGD 1.03
- Price Target Upside
- 101.96% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 3
- Revenue Growth Forecast
- 3.27%
- EPS Growth Forecast
- 43.59%
Scores
- Smart Score
- 8
- AI Score
- 53
